INmune Bio Inc <INMB.OQ> expected to post a loss of 38 cents a share - Earnings Preview
INmune Bio Inc INMB.OQ INMB.O is expected to show a rise in quarterly revenue when it reports results on August 7 for the period ending June 30 2025
The Boca Raton Florida-based company is expected to report revenue of $1.67 thousand, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for INmune Bio Inc is for a loss of 38 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for INmune Bio Inc is $7.00, about 61.6% above its last closing price of $2.69
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.47 | -0.47 | -0.43 | Beat | 8.5 |
Dec. 31 2025 | -0.54 | -0.40 | Beat | 25.9 | |
Sep. 30 2024 | -0.48 | -0.50 | -0.60 | Missed | -20.8 |
Jun. 30 2024 | -0.63 | -0.63 | -0.50 | Beat | 20.6 |
Mar. 31 2024 | -0.53 | -0.53 | -0.61 | Missed | -14 |
Dec. 31 2023 | -0.44 | -0.47 | Missed | -6.8 | |
Sep. 30 2023 | -0.39 | -0.39 | -0.48 | Missed | -21.5 |
Jun. 30 2023 | -0.39 | -0.40 | -0.36 | Beat | 9.2 |
This summary was machine generated August 5 at 22:08 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
